Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCH) Free Cash Flow (2022 - 2025)

Envoy Medical's Free Cash Flow history spans 4 years, with the latest figure at -$4.4 million for Q3 2025.

  • For Q3 2025, Free Cash Flow fell 21.84% year-over-year to -$4.4 million; the TTM value through Sep 2025 reached -$17.1 million, up 32.93%, while the annual FY2024 figure was -$18.9 million, 9.77% down from the prior year.
  • Free Cash Flow for Q3 2025 was -$4.4 million at Envoy Medical, up from -$4.5 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $1.0 million in Q3 2023 and bottomed at -$11.2 million in Q4 2023.
  • The 4-year median for Free Cash Flow is -$4.0 million (2023), against an average of -$3.8 million.
  • The largest YoY upside for Free Cash Flow was 119.74% in 2023 against a maximum downside of 910.85% in 2023.
  • A 4-year view of Free Cash Flow shows it stood at -$2.4 million in 2022, then plummeted by 361.4% to -$11.2 million in 2023, then skyrocketed by 59.19% to -$4.6 million in 2024, then increased by 3.88% to -$4.4 million in 2025.
  • Per Business Quant, the three most recent readings for COCH's Free Cash Flow are -$4.4 million (Q3 2025), -$4.5 million (Q2 2025), and -$3.7 million (Q1 2025).